Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)

NCT07037459 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT07037459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07037459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF)
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Recruiting
Start date
June 25, 2025
Completion date
September 29, 2030
Enrollment
5,056 (estimated)
Sites
657

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure with mildly reduced ejection fraction, heart failure with preserved ejection fraction, obesity